SAN DIEGO, March 21, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company
engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that data
from its successful pilot study with the University of Nebraska Medical Center will be presented in an abstract at the 2019 AACR
Annual Meeting, which is being held March 29 - April 3 at the Georgia World Conference Center in Atlanta.
Details of the poster presentation are as follows:
|
| Title: |
|
4587/11 - The N-terminal domain of HARS is a novel NRP2 ligand and can regulate NRP2-dependent macrophage
function |
| Presenter: |
|
Dr. Kaustubh Datta, Professor of Biochemistry and Molecular Biology at University of Nebraska Medical
Center |
| Session: |
|
Session PO.TB06.10 - Immunity in the Microenvironment |
| Date/Time: |
|
April 3, 2019 from 8:00am-12:00pm EDT |
| Location: |
|
Section 4 |
The poster may be accessed on the aTyr Pharma website at https://www.atyrpharma.com/our-science/publications/ following the presentation.
About ATYR1923
aTyr is developing ATYR1923 as a potential therapeutic for patients with interstitial lung diseases. ATYR1923, a
fusion protein comprised of the immuno-modulatory domain of histidyl tRNA synthetase (HARS) fused to the FC region of a human
antibody, is a selective modulator of neuropilin-2 that downregulates the innate and adaptive immune response in inflammatory
disease states. aTyr initiated a proof-of-concept Phase 1b/2a trial evaluating ATYR1923 in patients with pulmonary
sarcoidosis in the fourth quarter of 2018. This Phase 1b/2a study is a multiple-ascending dose, placebo-controlled,
first-in-patient study of ATYR1923 that has been designed to evaluate the safety, tolerability, steroid sparing effect,
immunogenicity and pharmacokinetics (PK) profile of multiple doses of ATYR1923. For the Phase 1b/2a trial, aTyr is
collaborating with the Foundation for Sarcoidosis Research (FSR), the nation’s leading nonprofit organization dedicated to finding
a cure for sarcoidosis and improving care for sarcoidosis patients. Under the terms of the collaboration, FSR will assist with
clinical trial site initiation and patient enrollment.
About aTyr
aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on
novel immunological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology,
the extracellular functionality of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential
pipeline of protein compositions derived from 20 tRNA synthetase genes. aTyr is focused on the therapeutic translation of the
Resokine pathway, comprised of extracellular proteins derived from the histidyl tRNA synthetase gene family. ATYR1923 is a
clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in
interstitial lung diseases and other immune-mediated diseases. For more information, please visit http://www.atyrpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act.
Forward-looking statements are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,”
“intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We
intend these forward-looking statements to be covered by such safe harbor provisions for forward-looking statements and are making
this statement for purposes of complying with those safe harbor provisions. These forward-looking statements, including
statements regarding the potential therapeutic benefits and applications of our product candidates; our ability to successfully
advance our product candidates, undertake certain development activities (such as the initiation of clinical trials, clinical trial
enrollment, the conduct of clinical trials and the announcement of top-line results) and accomplish certain development goals, and
the timing of such events; and the scope and strength of our intellectual property portfolio. These forward-looking
statements also reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on
the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions,
expectations, strategies and prospects, as reflected in or suggested by these forward-looking statements, are reasonable, we can
give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual
results may differ materially from those described in these forward-looking statements and will be affected by a variety of risks
and factors that are beyond our control including, without limitation, risks associated with the discovery, development and
regulation of our product candidates, the risk that we may cease or delay preclinical or clinical development activities for any of
our existing or future product candidates for a variety of reasons (including difficulties or delays in patient enrollment in
planned clinical trials), and the risk that we may not be able to raise the additional funding required for our business and
product development plans, as well as those risks set forth in our most recent Annual Report on Form 10-K, Quarterly Reports on
Form 10-Q and in our other SEC filings. Except as required by law, we assume no obligation to update publicly any
forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
Joyce Allaire
Managing Director, LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
